Last edition
News about "Jaeyong Ahn"
SK Bioscience Begins Study of Sarbecovirus Vaccine
SK bioscience has initiated a global phase I/II clinical trial of GBP511, a universal vaccine candidate targeting the Sarbecovirus family, leveraging its SKYCovione recombinant protein platform and nanoparticle technology as part of the company’s mid- to long-term strategy to advance next-generation vaccines for future pandemic preparedness.
Jaeyong Ahn | 30/01/2026 | By News Bureau
SK bioscience, MSD and Hilleman Advance Ebola Vaccine with CEPI Funding
he collaboration will receive up to USD 30 million in CEPI funding to support development of MSD’s Zaire ebolavirus vaccine, with a focus on improving manufacturing efficiency, enhancing thermostability and expanding affordable vaccine access in low- and middle-income countries.
Jaeyong Ahn | 23/01/2026 | By News Bureau
SK bioscience Submits IND Application for Phase 1/2 Trial of Adjuvanted Influenza Vaccine Candidate
SK bioscience has submitted an Investigational New Drug (IND) application to South Korea’s Ministry of Food and Drug Safety for Phase 1/2 clinical trials of its adjuvanted influenza vaccine candidate, NBP607B, aimed at boosting protection for older adults.
Jaeyong Ahn | 19/07/2025 | By Mrinmoy Dey | 149
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy